Sartorius

14.10.2024

DAX with a new run-up to record highs? US reporting season could help + Tonies: A box conquers the world + 5 DATES that will be important this week

The reporting season in the USA and the ECB's expected interest rate cut on Thursday should provide fresh impetus for the German stock market in the new week. Billions in economic aid for China should also go down well with the stock market. The DAX could set new record highs. - The weekly outlook.

https://www.deraktionaer.de/artikel/maerkte-forex-zinsen/dax-mit-neuem-anlauf-auf-rekordhoehen-us-berichtssaison-koennte-helfen-20368031.html

Small box, big success: the interactive audio platform from Tonies $TNIE (+0,57 %) not only makes children's eyes light up. The investors also have every reason to be happy.

https://www.deraktionaer.de/artikel/medien-ittk-technologie/tonies-eine-box-erobert-die-welt-20367911.html

5 DATES that will be important this week

• 1. ZEW economic expectations rise in October

The economic expectations of investors surveyed by the Center for European Economic Research for Germany are likely to have risen again in October for the first time after three consecutive declines. Economists surveyed by Dow Jones Newswires forecast that the index has risen to 9.0 (September: 3.6) points. The situation assessment index is expected to rise to 84.3 (minus 84.5) points. The Sentix economic index surveyed among the same group of people has also risen.

>>> Tuesday, 15.10.2024; 11:00

• 2. investment banking gives US institutions a boost

According to JP Morgan $JPM (+0,11 %) and Wells Fargo $WFC (+0,08 %) the other major US banks present their figures for the third quarter. In particular Morgan Stanley $MS (+0,16 %) and Goldman Sachs $GS (+0,16 %) with their relatively large investment banks, are likely to benefit from the fact that activity on Wall Street has picked up again. The universal banks Citigroup $C (+0,08 %) and Bank of America $BAC (+0,05 %) will also feel this. However, they are also noticing the waning tailwind in the interest-bearing business.

>>> Bank of America, Morgan Stanley, Citigroup (Tuesday), Goldman Sachs (Wednesday)

• Wells Fargo reported an 11% drop in third-quarter profit to USD 5.1 billion, but beat analysts' expectations due to higher revenues at the investment bank. This led to a rise in the stock in pre-market trading, indicating a positive market reaction despite the earnings decline.
• JPMorgan Chase exceeded analysts' expectations in the third quarter with a profit of 12.9 billion US dollars, which led to a rise in the share price in pre-market trading. This strong increase in earnings compensated for higher loan loss provisions and could have a positive impact on the share price.

• 3. focus at Sartorius is on the outlook

Sartorius $SRT (+0,71 %) is likely to have recorded a rather meagre business performance in the third quarter. Analysts' consensus expectations are for sales revenue to be roughly on a par with the previous year, but this is mainly due to a low basis for comparison and not yet a recovery in organic growth. The focus is on the forecast, which the DAX-listed laboratory equipment supplier lowered in July. Sartorius had referred to the high volatility and limited predictability of short-term business development and only held out the prospect of increasing demand momentum for the final quarter. The succession of Group CEO Joachim Kreuzburg, who is not seeking a further term of office after his contract expires in November 2025, is also unclear.

>>> Thursday, October 17, 2024; 07:00

• 4. the ECB takes an extra step downwards

The European Central Bank (ECB) will probably not be able to escape the pull of falling inflation rates and weaker economic indicators. Statements from ECB Governing Council members of all stripes and data suggest that the ECB will decide on Thursday to cut its key interest rate by 25 basis points to 3.25 percent - a month after trying to avoid exactly this impression. Normally, central banks try to avoid such abrupt swings. However, one must give the ECB credit for the fact that it would only be implementing its promise to adjust interest rates to the data situation.

>>> Thursday, 17.10.2024; 14:15

• 5 China's economic problems are worsening

Economic growth in China could also fall short of official targets in the third quarter of 2024, write the economists at Bank of America (BofA) in a research note. Gross domestic product (GDP) growth is likely to slow to 4.6 percent in the third quarter after 4.7 percent in the second quarter, the economists expect. Beijing has set itself a growth target of 5 percent for the year as a whole. The reluctance of Chinese politicians to take major economic measures, together with contradictory political goals, is contributing to the downturn. Many experts are concerned. Analysts at Gavekal warned at a briefing that deflation is on the way and there is little sign that Beijing's efforts to stabilize the property market and improve consumer and business sentiment are working. For the rest of the world, China's worsening problems are increasing the risk of a global economic slowdown and putting pressure on commodity prices, with a focus on China.

>>> Friday, October 18, 2024; 04:00

Monday: Stock market dates, economic data, quarterly figures

Stock market holiday Canada | Japan | US bond market (US equity markets are open, however)

Quarterly figures / company dates Europe

07:00 Fraport traffic figures for September

Untimed: Volkswagen Pre-Close-Call 3Q | Bawag quarterly figures

Economic data

• 02:00 SG: GDP 3rd quarter FORECAST: +2.0% yoy/+4.0% yoy previous: +0.4% yoy/+2.9% yoy
• 04:00 CN: Foreign trade September trade balance Forecast: +89.80 bn US dollars previous: +91.02 bn US dollars Exports Forecast: +6.0% yoy previous: +8.7% yoy
• Without time specification: AT: Opec oil market report October

19.07.2024 +++ Netflix continues to grow very strongly +++ TSMC with profit-taking +++ Airbus with "Lead" savings program +++ Sartorius with official profit warning +++

Netflix
$NFLX (+0,21 %) continues to grow unabated and wants to steal more viewers from traditional television. In the past quarter, the video streaming market leader gained a good eight million new customer households. There was also significant growth in sales and profits. Netflix also continues to reject bundled offers because it sees itself as a strong brand!

The shares of TSMC
$2330 fell by 2.0% despite strong results for the second quarter. High demand has given the chip manufacturer a jump in profits. Turnover rose by 40 percent to 674 billion Taiwan dollars. However, the share had recently benefited greatly from the high demand for semiconductors for AI applications and had risen to an all-time high.

The aircraft manufacturer Airbus
$AIR (+0,06 %) is clearly preparing for strong headwinds in its aircraft division. After recently informing investors that things are not going as well as expected this year, employees are now being prepared for a cost-cutting program. Although the plan is not backed up with figures, the program, called "Lead", is apparently to be implemented stringently.

The profit warning that everyone knew about is finally here. Sartorius
$SRT (+0,71 %) lowered its forecast for the year as a whole yesterday evening due to weak demand. In the first half of the year, sales amounted to EUR 1.68 billion, down 2.2 % on the previous year, although the second quarter in isolation already contributed slight growth of 3.6 %. Operating EBITDA fell by 8.8 % to EUR 471 million.

Friday: Stock market dates, economic data, quarterly figures

Small expiry day

ex-dividend of individual stocks

Suedzucker EUR 0.90

Procter & Gamble 1.01 USD

Colgate-Palmolive 0.50 US

Quarterly figures / company dates USA / Asia

13:00 American Express quarterly figures

13:00 Travelers Cos quarterly figures

13:00 Schlumberger quarterly figures

Quarterly figures / Company dates Europe

07:00 Sartorius Results 1H

08:00 Yara quarterly figures

08:00 Burberry Q1 sales

09:00 Sartorius PK

Economic data

• 08:00 DE: Producer prices June

FORECAST: +0.1% yoy/-1.6% yoy previously: 0.0% yoy/-2.2% yoy

• 08:00 UK: Retail Sales June

OUTLOOK: -0.5% yoy/+0.2% yoy previous: +2.9% yoy/+1.3% yoy

Position expanded. I have the feeling that all the hype surrounding biotech and innovative drugs has so far $SRT (+0,71 %) has passed us by. They serve many research-based pharmaceutical manufacturers and are therefore not so dependent on individual successes as to whether drugs are launched or not. In my view, there is a lot to be said for them in the long term, even if there are a few short-term uncertainties such as debt. Perhaps not the very best time to buy with the latest interest rate developments, but if you wait too long for the perfect moment, you won't buy at all.

Share analysis/share presentation ⬇️

Today we are talking about the company Sartorius: $SRT (+0,71 %)

What is Sartorius and what does it do?

Sartorius is a German company that specializes in the manufacture of laboratory and process technology. They offer a wide range of products and solutions for biopharmaceuticals, laboratories and the food industry. Sartorius supports research institutions and companies in the development and production of drugs, vaccines and other biotechnological products. Sartorius is known for its high-quality products, innovative technologies and its contribution to improving the healthcare industry.

Market capitalization:

Sartorius currently has a market capitalization of around 22.6 billion dollars.

Strengths of the share:

Some of Sartorius' strengths are:

- Innovation leadership: Sartorius is known for its continuous innovation in laboratory and process technology. They are constantly developing new products and solutions to meet the changing needs of the industry.

- Broad product portfolio: Sartorius offers a wide range of products ranging from laboratory instruments to consumables and process solutions. This enables them to serve customers in various industries and applications.

- Quality and reliability: Sartorius places great emphasis on the quality and reliability of their products. They ensure that their products meet the highest standards and provide customers with reliable performance.

- Customer Service: Sartorius places great emphasis on excellent customer service. They provide training, technical support and consulting services to help customers get the most out of their products.

- Sustainability: Sartorius is committed to sustainability and environmentally friendly practices. They are committed to the responsible use of resources and develop technologies that enable sustainable production.

- Global network: Sartorius has an extensive global network with subsidiaries and distribution partners in many countries. This enables them to support and serve customers worldwide.

- Industry expertise: Sartorius has many years of experience and extensive expertise in the fields of biopharmaceutical, laboratory and food technology. They understand the specific requirements and challenges of the industry and can offer customized solutions.

Share weaknesses:

Some weaknesses of Sartorius are:

- Dependence on specific industries: Sartorius is heavily involved in the biopharmaceutical and laboratory and process technology sectors. This means that the company is dependent on demand and developments in these industries. Changes in the industry could have a negative impact on Sartorius' business.

- Competition: In the laboratory and process technology sector, there are strong competitors offering similar products and solutions. Sartorius must constantly strive to differentiate itself from the competition and offer innovative solutions.

- Dependence on external suppliers: Sartorius is dependent on external suppliers for certain raw materials and components. If there are supply bottlenecks or quality problems with suppliers, this could have an impact on Sartorius' production and ability to deliver.

- Exchange rate risks: As Sartorius is a global company, it is subject to exchange rate fluctuations. Fluctuations in exchange rates can affect the cost of raw materials, production costs and the sale of products.

- Regulatory challenges: The biopharmaceutical and food industries are subject to strict regulatory requirements. Sartorius must ensure that its products and solutions comply with regulatory requirements, which can result in additional effort and costs.

A little more about the business model:

Sartorius is a company that specializes in the development and manufacture of products and solutions for the biopharmaceutical and laboratory and process technology sectors.

In the biopharmaceutical sector, Sartorius offers a wide range of products that are used in the manufacture of biopharmaceutical drugs. These include, for example, filtration systems, single-use bioreactors and laboratory instruments. These products help pharmaceutical companies to optimize their production processes and ensure the quality of their drugs.

In the area of laboratory and process technology, Sartorius offers solutions for various applications in laboratories and industrial processes. These include precision balances, pipettes, fermenters and measuring instruments. These products are used in laboratories and in production to perform precise measurements and improve the efficiency of processes.

Sartorius' business model is based on selling these products and solutions to customers in the biopharmaceutical and laboratory and process technology industries. The company emphasizes quality, innovation and customer service. Sartorius works closely with its customers to understand their individual needs and provide customized solutions.

In addition, Sartorius also offers services such as technical support, training and calibration to provide its customers with a comprehensive service.

Sartorius is a global company and works with customers all over the world. The company has a strong presence in key markets and continuously invests in research and development to create innovative products and solutions.

A little more about the industry:

Sartorius operates in the biopharmaceutical and laboratory and process technology industries. These industries are closely linked and play an important role in the development and manufacture of medicines. In biopharmaceuticals, biotechnological processes are used to produce medicines. Sartorius offers products and solutions that are used in these processes. In the laboratory and process technology sector, Sartorius supports laboratories and production processes with high-quality instruments and equipment. Sartorius is an important player in these industries and contributes to the further development of the healthcare industry.

When and where was Sartorius founded?

Sartorius was founded in 1870 in Göttingen, Germany, by Florenz Sartorius. Originally started as a scale factory, the company has evolved over the years into a leading provider of laboratory and process technologies. Today, Sartorius has subsidiaries worldwide and is known for its high-quality products and solutions in the fields of biopharmaceuticals, laboratory technology and process technology.

The goal of Sartorius :

Sartorius aims to make a positive contribution to the healthcare industry through its innovative biopharmaceutical and laboratory technology products and solutions. The company strives to support the research and development of medicines and improve the production of high-quality biopharmaceutical products. Sartorius emphasizes quality, precision and reliability to provide the best possible solutions to customers in the pharmaceutical and biotechnology industries. The goal is to promote the health and well-being of people worldwide and to have a lasting impact on the industry.

Your opinion:

Now I would like to hear your opinion on this stock in the comments.

I personally find the company very interesting and will continue to monitor it. It was an unknown company to me until recently, but that's exactly why I wanted to introduce you to the share.

What do you think of Sartorius and were you already familiar with the company?

Do you perhaps already have the share in your portfolio?

Please let me know in the comments.

Of course, this is not investment advice but just my own opinion, which I would like to share with you.

Depot review December 2023 - On the home stretch, 2023 was still able to make up for all the losses from 2022 and break the €250,000 mark 🚀

In keeping with the new year, there is also a new profile picture for the first time - an AI-generated elf who specializes in lembas and mithril trading.

But now to the portfolio update:

After November was already the second-best November of my investment career, December has now also gone into the books as the second-best. In total, a return of +3,2% for December.

This brings my performance for the year to +24,0% and was thus able to beat my benchmark, the MSCI World (+20.2%).

Tech stocks were the main winners in 2023. With almost +8.000€ is hardly surprising NVIDIA
$NVDA (-0,13 %) at the top. With +5,000€ and +4,000€ respectively then follow Palo Alto Networks $PANW (+0,01 %) and Meta
$META (+0,06 %)

Also Alphabet
$GOOG (+0,64 %) and Microsoft
$MSFT (-0,02 %) with each +3.000€ very strong this year

The main losers this year were healthcare, utilities, consumer staples and China. The biggest losers this year were:

• Pfizer $PFE (+0,22 %) -1.100€
• China ETF $MCHS (-1,93 %) -900€
• Nextera $NEE (-0,7 %) -900€
• Johnson & Johnson $JNJ (-0,14 %) -800€
• Procter & Gable $PG (-0,25 %) -500€

In total I bought again in December for ~2.500€ in December.

In total, my portfolio now stands at ~252.000€. This corresponds to an absolute increase of ~€74,000 in the current year 2023. ~43.000€ of this comes from price gains, ~2.500€ from dividends / interest and ~28.000€ from additional investments.

Thanks to the strong November and December, all price losses from 2022 have been made up.

Nevertheless, it has to be said that the last two years were not profitable overall. The portfolio has actually only grown through additional investments.

Dividend:

• Dividends in December were +23% above the previous year at ~€300
• For the year as a whole, dividends were +24% above the previous year at ~2.300€. In addition there was ~200€ in interest
• The following companies paid the highest dividends this year, all of which distributed more than €100: Amgen $AMGN (-0,36 %)
  Procter & Gamble
  $PG (-0,25 %)
  Unilever
  $ULVR (+0,24 %)
  Johnson & Johnson
  $JNJ (-0,14 %) and Starbucks
  $SBUX (-0,11 %)
  
• The highest dividend yields are achieved by Allianz
  $ALV (+0,65 %) with 9,5% on. In 2024 and a further dividend increase, I see a 10% yield here

Buys & sells:

• I bought again in December for approx. 2,500€
• As always, my savings plans were executed:
• Blue chipsItochu $8001 (-0,47 %) ASML $ASML (-0,48 %) Deere $DE (+0,04 %) Lockheed Martin $LMT (-0,12 %) MasterCard $MA (+0,06 %) Northrop Grumman $NOC (-0,12 %) NVIDIA $NVDA (-0,13 %) Republic Services $RSG (-0,1 %) Thermo Fisher $TMO (-0,28 %)
  
• GrowthSartorius $SRT (+0,71 %) Synopsys $SNPS (+0,88 %)
  
• ETFsMSCI World $XDWD Nikkei 225 $XDJP Invesco MSCI China All-Shares $MCHS and the WisdomTree Global Quality Dividend Growth $GGRP
• CryptoBitcoin $BTC and Ethereum $ETH
• Sales there were none in December

With another extremely strong performance in December, my portfolio broke through the €250,000 barrier. This really exceeds my wildest expectations that I had a year ago or even in October.

At the beginning of the year, my year-end target was €220,000 and my best-case scenario was €240,000.

What investments did you make outside of the stock market?

In 2022 I bought a balcony power plant installed. This has given me around 600kwh this year, saving me electricity costs of ~€200. In relation to the purchase price, this corresponds to a return of almost 30%.

In 2024, the topic of renting is also on the agenda, so far only investments have been made here, but from 2024 rental income should also start to flow.

Outlook for 2024:

I am now assuming an above-average stock market year in 2024. If we really do see a soft landing and some additional interest rate cuts from both the Fed and the ECB, this should give the markets a further tailwind. Of course, you have to bear in mind that November and December have already priced in a lot, 10% should be possible in any case.

I therefore see my assets at ~€300,000 at the end of 2024. This is mainly due to the lower investments I plan to make in 2024.

Overall, my savings rate will probably fall from €2,500-3,000 per month to "only" ~€2,000. This is mainly due to some private expenses that will be incurred in 2024.

What are your plans & expectations for 2024?

#dividends
#dividende
#rückblick
#depotupdate
#aktie
#stocks
#etfs
#crypto
#personalstrategy

Depot review September 2023 - September presents itself as always as a spoilsport and delivers the 4th negative September in a row for my portfolio

September is
is statistically the worst stock market month and also in the September 2023 this statistic proves to be true again.

In September my portfolio with -2.7%, my portfolio had a clearly negative performance. In contrast to September 2022 with -6.0% but a less bad development.

In the current year, my performance is thus only +14,5%but still above my benchmark (MSCI World +12.9%).

Nevertheless, this beats losses in the amount of ~6.500€ in September. in September. The biggest loser in September was NVIDIA $NVDA (-0,13 %) with over €1,100. Also Sartorius $SRT (+0,71 %) and ASML $ASML (-0,48 %) with a negative development.

On the plus side, there is not much positive in September, the best performance was still Amgen $AMGN (-0,36 %) with almost +8% and ~400€ price gains.

In total, I bought again in September for ~€2,500. In addition, there was a premium refund of over € 2,000 from my private health insurance for the year 2022 (this will be followed soon by a separate article including my investment strategy in relation to the private health insurance).

In total, my deposit thus stands slightly below the previous month at ~224.000€. This corresponds to an absolute increase of ~45.000€. in the current year 2023. ~24.000€ come from price increases, ~1.950€ from dividends / interest and ~19.000€ from additional investments.

Nevertheless, there is a shortfall of almost 15,000€ in price gains to make up for the ~38,000€ in price losses from 2022.

Dividend:

• The dividend comparison to the previous year is slightly more difficult this month, as Unilever paid out in August instead of September as usual and my Japan ETF will pay out in September instead of August.
• Thus the dividend is +10% above the previous year. Including the Unilever dividend, it would be approx. +28% and +20%, respectively, if my Japan ETF had paid out in August as before
• In the current year, dividends are up +26% after 9 months over the first 8 months of 2022 at ~€2,000

Purchases & Sales:

• Bought in May for ~2.500€
• Executed mainly my savings plans:
• Blue ChipsDeere $DE (+0,04 %) NVIDIA $NVDA (-0,13 %) ASML $ASML (-0,48 %) MasterCard $MA (+0,06 %) Republic Services $RSG (-0,1 %) Lockheed Martin $LMT (-0,12 %) Thermo Fisher $TOM2 (+0,24 %) Itochu $8001 (-0,47 %) Northrop Grumman $NOC (-0,12 %)
  
• GrowthSartorius $SRT (+0,71 %) Synopsys $SNPS (+0,88 %)
  
• ETFsMSCI World $XDWD Nikkei 225 $XDJP and the Invesco MSCI China All-Shares $MCHS
• Crypto: Bitcoin $BTC and Ethereum $ETH
• Sales there were none in August

With October now follows a statistically positive stock market month, which, however, can also tend to very strong downward swings (1987, 2008)

On average, however, October is about +0.5%. In my portfolio, October was positive in 2022 and 2021, but negative in the 3 years before (2018-2020).

What do you guys expect for October and especially the 4th quarter? Year-end rally, sideways trend or yet again significantly lower prices?

#dividends

#dividende

#rückblick

#depotupdate

#aktie

#stocks

#etfs

#crypto

#personalstrategy

Switched my Datagroup shares to Sartorius.

The weak phase is due to a special effect. I think it could be a one-time opportunity.

In addition, we are already reading again about some pandemics, etc.

Depot review July 2023 - Eerie, but still green figures 🤔🚀

July 2023 is a special month for me, as it marks the 119th month of my stock market career - This means there is nothing standing in the way of the 10th anniversary in August.

July was (to my surprise) another very strong month in the portfolio.

In July, my portfolio could +2,6% increase. In contrast to July 2022 with +8.7% but a weaker development.

In the current year, my performance is currently +18,0% and thus continues to outperform my benchmark (MSCI World +15.4%).

In July, NVIDIA again $NVDA performed extremely strongly in July with +12% / +€1,200. In percentage terms, Sartorius $SRT (+0,71 %) Block $SQ (+0,82 %) and Meta $META (+0,06 %) only 3 shares performed even better.

On the losing side, there were no spectacular developments in July. With Stryker $SYK (+0,32 %) and Hershey $HSY (+0,22 %) there are rather defensive stocks to be found.

In total, my portfolio stands at just under ~226.000€. This corresponds to an absolute growth of ~47.000€ in the current year in the current year 2023. ~32.000€ come from price increases, ~1.500€ from dividends / interest and ~14.000€ from additional investments.

However, there are still ~6,000€ of price gains missing to make up for the ~38,000€ of price losses from 2022.

Dividend:

• Dividend +15% compared to previous year
• Current year dividends are +23% over first 7 months 2022 at ~€1,350 after 6 months

Purchases & Sales:

• Bought in May for ~€3,800
• Executed mainly my savings plans:
• Blue ChipsLVMH $MC (-0,33 %) Novo Nordisk $NOVO B Apple $AAPL (+0,17 %) Home Depot $HD (+0,05 %) Microsoft $MSFT (-0,02 %) Nike $NKE (+0,07 %) Starbucks $SBUX (-0,11 %) Stryker $SYK (+0,32 %) Texas Instruments $TXN (+0,24 %)
  
• GrowthCrowdstrike $CRWD (+0,28 %) Mercadolibre $MELI (+0,67 %)
  
• ETFsMSCI World $XDWD Nikkei 225 $XDJP and the Invesco MSCI China All-Shares $MCHS
• Crypto: Bitcoin $BTC and Ethereum $ETH
• Sales there were none in July. For August, however, possibly flies the iShares Healthcare Innovation
  $2B78 (+0,14 %) out of my portfolio. This is the only sector ETF that I own and have saved for a while. All in all, though, I'm more convinced by the Big Pharma companies I already have in the portfolio.

This will be followed in August by Alimentation Couche-Tard
$ATD (+0,09 %) another new stock. The stock has been on my watchlist for a long time and is now finally available at Trade Republic.

Advantages from my point of view: My first stock from Canada, which is strongly represented especially there and in the Scandinavian countries. Regularly increasing profits and cash flow, which consequently lead to extremely strong dividend increases (for years over 20% p.a.). In addition, one of the few long-running stocks that has known only one path for years: from bottom left to top right.

And the crowning glory: With a P/E ratio of 16.5, it is also not overly expensive.

In Germany, the company is rather unknown or poorly represented. Exception since this year: The company has bought the entire German service station network of Total.

Looking ahead, I am very curious when we will see the first major setback in 2023? Probably in August on my 10 year stock market anniversary 😂.

But no matter what happens next, I will continue to stay fully invested and keep buying every month. I have already experienced enough crises in the ~10 years (Euro crisis, Syria, Crimea, Brexit, Trump election, Corona, inflation, Ukraine,...).

How did your portfolio perform in July? And when do you expect the first setbacks on the markets? Do you remain fully invested or do you currently reduce your share quota?

#dividende

#dividends

#personalstrategy

#depotupdate

#performance

#update

#rückblick

Depot review June 2023 - And it keeps going 🚀🚀🚀

The year 2023 continues to go extremely well in my depot. In June, my portfolio was able to +2,1% increase. In contrast to June 2022 with -4,6% again a clearly different development.

In the current year, my performance is currently +15,9% and thus continues to outperform my benchmark (MSCI World +12.7%).

Still strongly driven by NVIDIA $NVDA with +7% / + 650€. Even stronger in the month of June was only Palo Alto Networks $PANW (+0,01 %) with +18% / +1,300€

On the losing side, there were no spectacular developments in June. With Alphabet $GOOG (+0,64 %) Synopysy $SNPS (+0,88 %) Salesforce $CRM (-0,38 %) Crowdstrike $CRWD (+0,28 %) and Mercadolibre $MELI (+0,67 %) the losers were more likely to be found in the tech/growth sector.

In total my portfolio stands at over 216.000€. This corresponds to an absolute growth of ~38.000€. in the first half of 2023. ~26,000€ of this comes from price increases, ~1,400€ from dividends / interest and ~10,000€ from additional investments.

Dividend:

• Dividend +9% compared to previous year
• At Encavis $ECV (+0,03 %) there was unfortunately a cancellation of the dividend this year. Despite the cancellation, my dividend was able to grow almost double-digit (On getquin, the Encavis dividend is still included as a forecast, which is why it shows an incorrect +18% vs. previous year)
• In the current year, dividends after 6 months are up +26% over the first 6 months of 2022 at ~€1,300

Purchases & Sales:

• Bought in May for ~4.000€
• Executed mainly my savings plans:
• Blue ChipsASML $ASML (-0,48 %) Alphabet $GOOG (+0,64 %) Deere $DE (+0,04 %) Lockheed $LMT (-0,12 %) Mastercard $MA (+0,06 %) Northrop $NOC (-0,12 %) Republic Services $RSG (-0,1 %) Thermo FIsher $TMO (-0,28 %) and as a new investment Itochu $8001 (-0,47 %)
  
• GrowthSartorius $SRT (+0,71 %) and Synopsys $SNPS (+0,88 %)
  
• ETFsMSCI World $XDWD Nikkei 225 $XDJP and the Invesco MSCI China All-Shares $MCHS
• Crypto: Bitcoin $BTC and Ethereum $ETH
• Sold with the BASF $BAS (+0,61 %) Share another part of my (very small) Germany share. For this I have created a standalone post on why I want to further reduce my Germany share.

Next month, another new share will probably follow with Novo Nordisk $NOVO B as I continue to see strong growth in the pharma sector and Novo Nordisk has an absolutely convincing track record in terms of profit and sales growth. Health, especially with regard to obesity, will remain an extreme challenge for the future in my eyes.

Furthermore, I am currently toying with the idea of changing my China ETF into a distributing ETF. I would like to remain invested in China, but I am also aware of the risks. In terms of dealing with Russian stocks (total loss of shareholders), a distributing ETF has a big advantage: you regularly get a portion back via dividends. In contrast to an accumulating fund, this reduces the risk of a total loss.

Furthermore, I am very curious to see what the second half of the stock market will bring. Will we continue to see an extremely strong recovery on the stock market and will the recession worries catch up with us at some point?

How did your portfolio perform in June? And what are your expectations for the second half of the year?

#dividende

#dividends

#personalstrategy

#depotupdate

#performance

#update

#rückblick

Finally gone - Germany share successfully reduced further

I have finally thrown the BASF share out of the portfolio and thus further reduced my Germany share.

With Allianz $ALV (+0,65 %) (bought at 119 euros; dividend yield almost 10%), Bechtle $BC8 (+0,28 %) , Sartorius $SRT (+0,71 %) and Encavis $ECV (+0,03 %) only 4 German companies remain.

While Allianz will definitely stay due to its high personal dividend yield, Bechtle and Sartorius will continue to be bought or saved.

Encavis will be kept, but not bought further.

Thus my Germany share is less than 5%.. The trend is still slightly downward.

The current environment in Germany is simply far too unattractive, especially for extremely energy-intensive companies like BASF. The large investments in China are of course also associated with a certain risk.

As a result, I do not see any positive effects for the share price development in the foreseeable future. The business trend could also point more in the direction of a significant dividend cut next year. The share buyback program was terminated prematurely and not executed in full. Not to mention a possible recession.

For me, there is no sensible reason to hold on to this share.

#sell
#stocks
#portfolio
#dividende